Delving into the Latest Updates on Autologous Cord Blood Stem Cells(Sutter Health) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication-

Inactive Indication

Autistic Disorder

Originator Organization

Sutter Health

Active Organization-

Inactive Organization

Sutter Health

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Evaluate the efficacy of one infusion of stem cells from autologous umbilical cord blood in patients with autism over six months after infusion as measured by changes in expressive and receptive language.
Also demonstrate improved behavior, learning, and changes in Serum tumor necrosis factor alpha (TNF-α), tumor necrosis factor beta (TNF-β), interleukin 1-alpha (IL-1α), interleukin 1-beta (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), and interleukin 13 (IL-13).

Start Date01 Aug 2012

Sponsor / Collaborator

Sutter Health

100 Clinical Results associated with Autologous Cord Blood Stem Cells(Sutter Health)

Login to view more data

100 Translational Medicine associated with Autologous Cord Blood Stem Cells(Sutter Health)

Login to view more data

100 Patents (Medical) associated with Autologous Cord Blood Stem Cells(Sutter Health)

Login to view more data

100 Deals associated with Autologous Cord Blood Stem Cells(Sutter Health)

Login to view more data